Search Results
WCGC 2012: Anti-angiogenic trials; key highlights of the 14th WCGC - Prof Eric Van Cutsem
2014 GICC Eric Van Cutsem, Belgium
Anti-angiogenic agents and cancer stem cells
Eric Van Cutsem: 'Realities of #ColorectalCancer'
Dr. Van Cutsem Discusses Regorafenib for the Treatment of Patients With Chemorefractory mCRC
Regorafenib Lengthens Suvival in Colorectal Cancer with KRAS Mutation
WCGC 2012: Exploring new targets in GI cancer - Prof Josep Tabernero
Dr. Rugo on Proliferation as an Anti-Angiogenesis Marker
Targeted Therapy for mCRC
Dr. Cutsem on Challenges of Targeted Therapies in Gastric Cancer
EMCCC 2010: Individualisation and personalisation of colorectal cancer treatments
Maintenance treatment or stop and go: What is the standard?
